AQVESME

Peak

mitapivat

Agios Pharmaceuticals

NDAORALTABLETPriority Review

Approved

Feb 2022

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Pyruvate Kinase Activators

Pharmacologic Class:

Pyruvate Kinase Activator

Indications (3)

anemia in adults with alpha-beta-thalassemia anemia

Loss of Exclusivity

LOE Date

Jul 31, 2041

187 months away

Patent Expiry

Jul 31, 2041

Exclusivity Expiry

Feb 17, 2029

Patent Records (5)

Patent #	Expiry	Type	Use Code
RE49582	Feb 24, 2031	SubstanceProduct	—
10632114	May 3, 2032		U-3320
9682080	May 3, 2032		U-3319
9980961	May 3, 2032		U-3319
9193701	Oct 26, 2032		U-3319

Company

Agios Pharmaceuticals

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers